<DOC>
	<DOCNO>NCT01571297</DOCNO>
	<brief_summary>The purpose study evaluate effect RM-131 gastric emptying , gastroparesis symptom , safety tolerability RM-131 compare placebo patient Type 1 Type 2 diabetes mellitus gastroparesis . The study design evaluate efficacy safety multiple dose regimens RM-131 . Study drug ( RM-131 placebo ) administer subcutaneously blind fashion .</brief_summary>
	<brief_title>Phase 2 Study Evaluate Safety &amp; Efficacy RM-131 Administered Patients With Diabetic Gastroparesis</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Diabetes Complications</mesh_term>
	<criteria>Able provide write informed consent prior study procedure willing able comply study procedure . Type 1 Type 2 diabetes mellitus HbA1c ≤11 % screening . Diabetic gastroparesis define least 3 month history symptom suggestive gastroparesis ongoing basis . Average Gastroparesis Cardinal Symptom Index Daily Diary ( GCSIDD ) &gt; 2.6 Visit 2 . History nausea and/or vomiting/emesis least week 2 week prior Visit 1 . Delayed gastric empty confirmed screen abnormal gastric empty breath test ( GEBT ) , define halfemptying time ( t½ ) &gt; 79 minute . Stable concomitant medication define change regimen least 2 week prior Visit 2 . No use metoclopramide , erythromycin antiemetic least 2 week prior Visit 2 . Body mass index &gt; 18 kg/m2 . Female patient must negative serum urine pregnancy test must lactate . For female able bear child , hormonal ( i.e. , oral , implantable , injectable ) singlebarrier method , doublebarrier method birth control must use throughout study . Female patient unable bear child must document electronic case report form ( eCRF ) ( i.e. , tubal ligation , hysterectomy , postmenopausal [ define minimum one year since last menstrual period ] ) . Postmenopausal status confirm FSH . Currently receive parenteral feeding ; presence nasogastric enteral tube feed decompression . History gastric surgery fundoplication , gastrectomy , gastric pacemaker placement , vagotomy , bariatric procedure . History pyloric injection botulinum toxin within 6 month screen . Persistent daily vomit . Patients clinical suspicion upper gastrointestinal obstruction must evaluate per standard care , obstruction rule screening . Currently take opiate . Currently take GLP1 amylin analog . Allergic intolerant egg , wheat , milk algae , component GEBT study meal . History anorexia nervosa , bingeeating bulimia within 5 year . ALT AST &gt; 2 X upper limit normal screening . History intestinal malabsorption pancreatic exocrine disease . Requires hemodialysis endstage renal disease . History human immunodeficiency virus ( HIV ) infection . Clinically significant neurologic psychiatric disorder likely impact compliance protocol requirement . Poor venous access inability tolerate venipuncture . Participation clinical study within 30 day prior dose present study . Any reason , opinion Investigator , include renal , hepatic cardiopulmonary disease , significant acute ECG abnormality would confound proper interpretation study expose patient unacceptable risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Delayed Gastric Emptying</keyword>
	<keyword>Gastroparesis</keyword>
	<keyword>Gastrointestinal Motility Disorder</keyword>
</DOC>